-31.6%
CRCL vs MRNA
+945.0%
-976.6%
-55.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.2% | +13.1% | -11.9% | 0.0% |
| 7D | -6.8% | +20.6% | -27.5% | -8.4% |
| 30D | -8.6% | +27.1% | -35.8% | -10.7% |
| 3M | +20.3% | +353.4% | -333.0% | -4.1% |
| 6M | -36.3% | +446.3% | -482.6% | -53.6% |
| YTD | -4.0% | +776.2% | -780.2% | -42.3% |
| 1Y | -31.6% | +987.9% | -1,019.5% | -63.5% |
| All | -31.6% | +945.0% | -976.6% | -63.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling